1. Pyruvate kinase M2 overexpression and poor prognosis in solid tumors of digestive system: evidence from 16 cohort studies
- Author
-
Wu JY, Hu LR, Chen MY, Cao WJ, Chen HC, and He TP
- Subjects
Digestive system ,Meta-analysis ,Solid tumors ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Prognostic value ,lcsh:RC254-282 ,Pyruvate kinase M2 - Abstract
Jiayuan Wu,1,* Liren Hu,2,* Manyu Chen,3 Wenjun Cao,4 Haicong Chen,5 Taiping He4 1Nutritional Department, the Affiliated Hospital of Guangdong Medical University, 2Department of Epidemiology and Health Statistics, School of Public Health, Guangdong Medical University, 3Department of Oncology, the Affiliated Hospital of Guangdong Medical University, 4School of Public Health, Guangdong Medical University, 5Department of Orthopedics, the Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, People’s Republic of China *These authors contributed equally tothis work Purpose: The expression of pyruvate kinase M2 (PKM2) has been linked to tumor formation and invasion. Specifically, the relationship between high PKM2 expression and prognosis has been evaluated in solid tumors of digestive system. However, the prognostic value of PKM2 remains controversial. Methods: A literature search of PubMed, Embase, and Cochrane databases was conducted until October 2015. The end point focused on overall survival (OS). The pooled hazard ratio (HR) or odds ratio and the 95% confidence intervals were calculated to correlate PKM2 overexpression with OS and clinicopathological characteristics by employing fixed- or random-effects models, depending on the heterogeneity of the included studies. Results: We identified 18 cohorts in 16 studies involving 2,812 patients for this meta-analysis. Overall, the combined HR for OS in all tumor types was 1.74 (1.44–2.11; P
- Published
- 2016